20210 – Registry study with Breast Cancer Index

Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

17079 – FLEX Registry: Evaluate New Gene Express

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

21236 – DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing ¨C Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

22159 – Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

22101 – Ph3 Imlun vs Endo ER+ HER2- BC

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

21235 – COMET: Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC

A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)

20186 – Ph2 Tumor-Agnostic Precision TAPISTRY

TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)